Mind + Muscle

technical minds + legal muscle


dig deep

New Patent Battleground: Inter Partes Reviews Besiege Innovators

  • 12.14.15

Eldora Ellison, Ph.D., is quoted in IN VIVO magazine's article "New Patent Battleground: Inter Partes Reviews Besiege Innovators," that discusses the use of inter partes reviews (IPRs) in the biopharmaceutical industry since the inception of the America Invents Act (AIA).

Dr. Ellison, who has worked on 55 IPR proceedings for patent owners and petitioners, discussed the alarming rate at which statistics indicate patents are killed at the Patent Trial and Appeal Board (PTAB). Though the numbers seem bleak, Dr. Ellison argues the kill rate varies depending on the way they are viewed.

"I see it as sort of a funnel," she said. At a given time a thousand claims may be challenged. Some of these cases will settle and on a few occasions the patent owner or petitioner will give up and request an adverse judgment. Maybe 25% of the total challenged claims are found unpatentable, Dr. Ellison says. But for those that make it to a final written decision where the PTAB judges decide patentability, about 80% may be found unpatentable.

Related People

Related Services

Sort By Media Type

Sort By Media Type
  • AlertAlert
  • BriefsBriefs
  • Comments to USPTOComments to USPTO
  • Design Patent Case DigestDesign Patent Case Digest
  • MultimediaMultimedia
  • News & ArticlesNews & Articles
  • Press ReleasePress Release
  • VideoVideo
  • WebinarWebinar

Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.